Key Points
- COO Ian Michael Estepan sold 13,187 shares of Sarepta on Dec. 16 at an average price of $22.31 for about $294,202, leaving him with 193,300 shares (a 6.39% reduction, valued ~ $4.31M).
- Sarepta (SRPT) is trading down (~3.8%) near $20.34 with a $2.13B market cap after reporting a quarterly EPS miss (-$0.13 vs $0.02) despite revenue beating estimates ($399.4M), and carries a MarketBeat consensus rating of "Hold" with a $33.68 target.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) COO Ian Michael Estepan sold 13,187 shares of the business's stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the transaction, the chief operating officer owned 193,300 shares of the company's stock, valued at approximately $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Sarepta Therapeutics Trading Down 3.8%
Shares of SRPT opened at $20.34 on Friday. The firm's 50 day simple moving average is $20.78 and its 200 day simple moving average is $20.64. The company has a market capitalization of $2.13 billion, a P/E ratio of -6.76 and a beta of 0.54. Sarepta Therapeutics, Inc. has a 1-year low of $10.41 and a 1-year high of $129.84. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.95 and a quick ratio of 1.79.
Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.15). The company had revenue of $399.36 million for the quarter, compared to the consensus estimate of $331.51 million. Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.The business's revenue was down 14.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.62 earnings per share. Sell-side analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Sarepta Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in SRPT. iSAM Funds UK Ltd bought a new position in shares of Sarepta Therapeutics in the 3rd quarter worth about $25,000. Ancora Advisors LLC boosted its stake in Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 1,000 shares in the last quarter. Byrne Asset Management LLC purchased a new stake in Sarepta Therapeutics in the third quarter worth about $33,000. Allworth Financial LP increased its stake in shares of Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 1,721 shares in the last quarter. Finally, Parallel Advisors LLC lifted its holdings in shares of Sarepta Therapeutics by 165.3% during the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 1,256 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a "sell" rating on shares of Sarepta Therapeutics in a report on Monday, August 25th. Wells Fargo & Company decreased their target price on Sarepta Therapeutics from $50.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, November 5th. Wedbush assumed coverage on shares of Sarepta Therapeutics in a report on Tuesday, December 9th. They issued an "outperform" rating and a $32.00 price target on the stock. Mizuho raised shares of Sarepta Therapeutics from a "neutral" rating to an "outperform" rating and boosted their price objective for the company from $19.00 to $26.00 in a research report on Wednesday, November 5th. Finally, Guggenheim dropped their target price on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a "buy" rating for the company in a research report on Wednesday, November 5th. Nine equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have assigned a Sell rating to the company. According to MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $33.68.
Check Out Our Latest Report on Sarepta Therapeutics
About Sarepta Therapeutics
(
Get Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
